{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-014760","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.064296+00:00","generated_at":"2026-05-30T03:36:26.155109+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeuroBo Q3 net loss $5.7M, cash $21.7M; positive Phase 1 SAD data for obesity drug DA-1726","bullets":["Net loss of $5.7M (EPS -$0.55) for Q3 2024 vs. $3.8M net loss ($0.75 per share) in Q3 2023.","Cash at Sept 30, 2024: $21.7M; expected to fund operations into Q3 2025.","Positive top-line data from SAD Part 1 of Phase 1 trial for DA-1726: safe, tolerable, dose-linear PK; additional cohorts exploring MTD.","DA-1241 Phase 2a MASH trial: top-line data expected in December 2024.","Entered joint research agreement with Dong-A ST and ImmunoForge for once-monthly formulation of DA-1726."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-014760","json":"https://secwatch.observer/filing/0001558370-24-014760.json","markdown":"https://secwatch.observer/filing/0001558370-24-014760.md","text":"https://secwatch.observer/filing/0001558370-24-014760.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024014760/0001558370-24-014760-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024014760/nrbo-20241107x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:36:26.155109+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}